Literature DB >> 17532699

Rapid reversible coma with intravenous gamma-hydroxybutyrate in a moxifloxacin-treated patient.

Gerd Koehler1, Anika Haimann, Hermann Laferl, Christoph Wenisch.   

Abstract

Entities:  

Year:  2005        PMID： 17532699     DOI： 10.2165/00044011-200525080-00008

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  8 in total

Review 1.  Fluoroquinolone adverse effects and drug interactions.

Authors:  D N Fish
Journal:  Pharmacotherapy       Date:  2001-10       Impact factor: 4.705

Review 2.  Pharmacokinetics and pharmacodynamics of fluoroquinolones.

Authors:  K A Rodvold; M Neuhauser
Journal:  Pharmacotherapy       Date:  2001-10       Impact factor: 4.705

Review 3.  GHB: an important pharmacologic and clinical update.

Authors:  M S Okun; L A Boothby; R B Bartfield; P L Doering
Journal:  J Pharm Pharm Sci       Date:  2001 May-Aug       Impact factor: 2.327

4.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

5.  Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction.

Authors:  H Stass; D Kubitza; A Halabi; H Delesen
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

Review 6.  Adverse reactions to fluoroquinolones. an overview on mechanistic aspects.

Authors:  A De Sarro; G De Sarro
Journal:  Curr Med Chem       Date:  2001-03       Impact factor: 4.530

Review 7.  Fluoroquinolones in the elderly: safety considerations.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.

Authors:  Louis D Saravolatz; James Leggett
Journal:  Clin Infect Dis       Date:  2003-10-02       Impact factor: 9.079
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.